AlphAIAlphAI — Financial news for AI agents
finance.yahoo.comSEP 241 min read$GKOS

Glaukos Corporation (GKOS) Stock Forecasts

Argus lowered its target price for Glaukos Corporation (GKOS) to $168.00. The company focuses on ophthalmic treatments for glaucoma, corneal disorders, and retinal diseases.

Original reporting
finance.yahoo.com
Published Sep 24, 2026, 12:23 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 24, 2026, 2:55 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefMarket movers
Primary signal
$GKOS
Bearish
medium confidence
Mentioned
$GKOS
Relevance
7/10
AlphAI data visualization · based on finance.yahoo.com
Decision brief

The 30-second read

$GKOSBearishMed
01

Why it matters

Analyst downgrade signals concerns about growth or trial outcomes.

02

Market read

Target price reduction may trigger sell pressure in GKOS and related biotech stocks.

03

What to watch

Potential pipeline milestones not reflected in the target.

Relevance 7/10Novelty 7/10Timing: today

Background

Glaukos Corp develops dropless therapies for eye diseases.

Company-level read

Ticker impact

$GKOSBearishMedium confidence
Context

Analyst lowers Glaukos Corp target price to $168.00

Expected impact

Potential short-term decline of 3-5%

Evidence & confidence

Analyst price target cuts often precede sell pressure, especially for niche biotech.

Market effects

Sector

May weigh on other ophthalmic biotech stocks.

Regional

Limited to US biotech sector.

Global

Minimal global impact.

Counterpoint

What could challenge this read

Target cut could be premature if upcoming trial data is positive.

Key entities

  • Company
    Glaukos Corp

    Ophthalmic pharmaceutical and medical technology firm.

Read at source← All news

Related articles

OCT 8
$GKOSMedAI 8/10

Glaukos' Epioxa Shows Durable Benefits At Three Years In Keratoconus Study

Glaukos (GKOS) reported positive three-year data from a Phase 3 extension study of Epioxa, its corneal cross-linking therapy for keratoconus. The study showed durable efficacy and a favorable safety profile, with treated eyes showing sustained improvement in corneal curvature and visual acuity. GKOS reported a narrowed net loss and 50% sales growth in Q2 2026, with 2026 net sales guidance of $680M-$700M. The stock is up 6.55% on the day.

rttnews.com2 min
OCT 7
$GKOSMed

Why is Glaukos stock surging today?

Glaukos Corp (GKOS) stock rose 5.3% to $170.21 after announcing Q3 2026 earnings release on October 28 and a keratoconus awareness campaign with NBA Champion Stephen Curry. Analysts have a consensus price target of $180.54. GKOS reported record Q2 sales up 50% YoY and raised 2026 revenue guidance to $680M-$700M.

investing.com2 min
AUG 25
$GKOSHighAI 8/10

Glaukos Market Cap More Than Doubles in a Year to $11B

Glaukos Corp.'s market cap has more than doubled to $11 billion in a year, driven by expanding into new eye care markets and record Q2 sales of $185.6 million. The company raised its full-year guidance and saw its shares rise over 15% post-earnings. Key products include iDose TR for glaucoma and Epioxa for keratoconus, with several other products in development.

ocbj.com2 min
AUG 20
$GKOSMed

GKOS Stock Surges 67% Year to Date: What's Driving the Rally?

Glaukos (GKOS) shares have risen 67.9% year-to-date, driven by strong revenue growth and product launches. Q2 revenue increased 49.5% to $185.6M, prompting raised 2026 guidance to $680-700M. Growth is attributed to iDose TR and Epioxa, with international expansion and a broad pipeline also contributing. Competitors include Alcon (ALC), Sight Sciences (SGHT), and AbbVie (ABBV). Risks include reimbursement and competition.

tradingview.com2 min